Recent Articles By The Author
Few parts of the market have more volatility than the small caps in this sector.
A look at the financials as earnings season kicks into high gear.
Here are updates on small biotech/biopharma names I have profiled before.
The way I do that is by using buy-write option strategies.
Construction spending hasn't sent ambivalent signals in 2019.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...